Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 9128 results

  1. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  2. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  4. Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 31 July 2026.

    Technology appraisal guidance
    In consultation

  5. Bladder cancer: diagnosis and management (update): scoping

    We are listening to your views on this NICE guideline. Comments close 6 August 2026.

    NICE guideline
    In consultation

  6. Post-traumatic stress disorder

    Topic prioritisation

    Quality standard
    Topic prioritisation

  7. Anxiety Disorders

    Topic prioritisation

    Quality standard
    Topic prioritisation

  8. Technologies for diagnosing endometriosis in primary care: early use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 27 July 2026.

    In consultation

  9. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]

    Awaiting development Reference number: GID-TA12466 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  15. Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date: TBC

    Technology appraisal guidance
    In development